Ataxia is the defect in normal movements like walking, speaking, eating swallowing etc. It is caused most commonly by damage to the brain stem or cerebellum that regulates movements. There are over 50 ...

Spinocerebellar ataxia type 1 (SCA1) primarily affects the brainstem, spinocerebellar tracts and cerebellar Purkinje cells. Patients with SCA1 develop progressive ataxia of limb and gait, as well as ...

Spinocerebellar ataxia type 7 (SCA7) is an autosomal-dominant, late-onset, slowly progressive disorder, primarily characterized by gradual loss of motor coordination, resulting from dysfunction and ...

A clinical trial conducted by Prof. Alexandra Durr's team (Sorbonne University.AP-HP) at the Paris Brain Institute and the Pitié-Salpêtrière Hospital AP-HP shows that despite the hopes raised in ...

Spinocerebellar ataxias are a group of neurodegenerative diseases characterized by the degeneration of Purkinje cells, a major class of neurons in the cerebellum. The resulting cerebellar dysfunction ...

Worldwide, only a handful of patients are known to suffer from episodic ataxia type 6, a neurological disease that causes transient loss of muscle control. The cause lies in a mutation that changes a ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Riluzole did not improve clinical or radiological ...

WOODBRIDGE, Conn., February 06, 2025--(BUSINESS WIRE)--Cure Rare Disease (CRD) announced it has been awarded a $5.69 million grant from the California Institute for Regenerative Medicine (CIRM) to ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The trial will evaluate VO659, an antisense ...

A research team headed by Specially Appointed Associate Professor Tomohiko Ishihara and Professor Osamu Onodera at Niigata University, in collaboration with Professor Yoshitaka Nagai at Kindai ...

VO659 is the only clinical-stage candidate targeting the CAG repeat expansion that causes these diseases VO659 was designed to preferentially reduce mutant HTT and spare wild-type HTT Phase 1/2a ...